Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-06-18

Kinetics for Drug Discovery (K4DD)

Objetivo

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles.
This hindsight knowledge needs to be converted into data-driven guidelines and easily accessible high-throughput assays for future drug discovery and fuels the K4DD consortium of over 20 partners, EFPIA members, universities, research institutes and SMEs. Our integrated approach will lead to the definition of any compound in terms of its target ‘kinotype’, next to affinity and selectivity. For us, integration means analyzing the kinetic behavior of different targets (GPCRs, kinases, proteases) across the three work packages. The partners in the consortium are European key players: they elucidate(d) structures of GPCRs and kinases, are at the forefront of bioanalytical techniques, e.g. surface plasmon resonance, are world-leaders in PKPD modeling, and bring the best of computational resources for e.g. molecular dynamics calculations. Thus, we study the drug-target interaction from picoseconds to >hours, for both soluble and membrane-bound proteins.
At the end of the consortium’s lifetime we anticipate that kinetic aspects of the drug-target interaction can routinely be studied in robust and accessible assays within and outside the consortium, that editors and reviewers routinely ask for a compound’s kinetic data next to its affinity and selectivity, that ‘kinotypic’ knowledge helps define the target product profile and guide the subsequent lead finding and optimization process, and that kinetic guidelines for predictive PKPD modeling approaches are the logical consequence of our efforts.
Thus, the overall ambition of the consortium is to instill lasting kinetic awareness into the pharma community.

Ámbito científico

Programa(s)

Tema(s)

Convocatoria de propuestas

IMI-JU-04-2011
Consulte otros proyectos de esta convocatoria

Régimen de financiación

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinador

BAYER AKTIENGESELLSCHAFT
Aportación de la UE
Sin datos
Dirección
KAISER-WILHELM-ALLEE 1
51373 Leverkusen
Alemania

Ver en el mapa
Región
Nordrhein-Westfalen Köln Leverkusen, Kreisfreie Stadt
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Investigador principal
Anke Mueller-Fahrnow (Dr.)
Contacto administrativo
Burkhardt Neumann (Mr.)
Enlaces
Coste total
Sin datos

Participantes (20)

Compartir esta página

Descargar

Última actualización: 15 Febrero 2022

Mi folleto

Permalink: https://cordis.europa.eu/project/id/115366/es

European Union, 2024